Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Pfizer, BMS, Crescendo Bioscience, and Abbott and (more than $10,000 each) from Roche/Genentech, UCB, Centocor, Amgen, and the Consortium of Rheumatology Researchers of North America (CORRONA), and has received research support from Amgen, UCB, CORRONA, Genentech, Centocor, Pfizer, and Crescendo Bioscience.
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
Version of Record online: 28 NOV 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 12, pages 1794–1803, December 2012
How to Cite
Curtis, J. R., van der Helm-van Mil, A. H., Knevel, R., Huizinga, T. W., Haney, D. J., Shen, Y., Ramanujan, S., Cavet, G., Centola, M., Hesterberg, L. K., Chernoff, D., Ford, K., Shadick, N. A., Hamburger, M., Fleischmann, R., Keystone, E. and Weinblatt, M. E. (2012), Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res, 64: 1794–1803. doi: 10.1002/acr.21767
- Issue online: 28 NOV 2012
- Version of Record online: 28 NOV 2012
- Accepted manuscript online: 26 JUN 2012 10:17AM EST
- Manuscript Accepted: 8 JUN 2012
- Manuscript Received: 24 JAN 2012
- Crescendo Bioscience
- Biogen Idec
- NIH. Grant Numbers: AR053351, AR058964, AR058989, AR057133
- Agency for Healthcare Research and Quality. Grant Number: R01HS018517
Additional Supporting Information may be found in the online version of this article.
|ACR_21767_sm_SupplTable1.doc||30K||Supplementary Tables 1 and 2|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.